Thomas P. Cujec
12Patents
6h-index
17Co-inventors
63Inventor score
Filing activity: Oct 3, 1997 → Feb 2, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8012931B2 | Modified FGF-21 polypeptides and their uses | Emerging Cross-Sectional Technologies | 65 | Active |
| US8383365B2 | Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives | Emerging Cross-Sectional Technologies | 48 | Active |
| US7632924B2 | Antigen-binding polypeptides and their uses | Chemistry; Metallurgy | 46 | Expired |
| US9079971B2 | Modified FGF-21 polypeptides comprising non-naturally occurring amino acids | Emerging Cross-Sectional Technologies | 18 | Active |
| US9517273B2 | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids | Emerging Cross-Sectional Technologies | 16 | Active |
| US9975936B2 | Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids | Emerging Cross-Sectional Technologies | 12 | Active |
| US9175083B2 | Antigen-binding polypeptides and their uses | Chemistry; Metallurgy | 6 | Active |
| US10377805B2 | Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses | Emerging Cross-Sectional Technologies | 2 | Active |
| US5994055A | HIV trans-activator Tat binding to CDK7 and activation of CTD phosphorylation | Chemistry; Metallurgy | 2 | Expired |
| US10961291B2 | Modified FGF-21 polypeptides and their uses | Emerging Cross-Sectional Technologies | 1 | Active |
| US6159684A | HIV trans-activator TAT binding to CDK7 and activation of CTD phosphorylation | Chemistry; Metallurgy | 0 | Expired |
| US11993637B2 | Modified FGF-21 polypeptides with non-naturally encoded amino acids | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.